Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir

Pediatr Infect Dis J. 2021 May 1;40(5):457-459. doi: 10.1097/INF.0000000000003066.

Abstract

Use of antiretrovirals is associated to body fat accumulation. We measured body composition in adolescents living with HIV switched to a dolutegravir-containing regimen. Trunk fat and trunk/body fat ratio markedly increased after 12 months. Total and low density lipoprotein cholesterol decreased after 3 months. Increase in trunk fat may put at risk of future cardiovascular problems, despite improvement in the lipid profile.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Fat / drug effects
  • Adolescent
  • Anti-Retroviral Agents / metabolism
  • Anti-Retroviral Agents / therapeutic use*
  • Body Fat Distribution*
  • Cohort Studies
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV Integrase Inhibitors / metabolism
  • HIV Integrase Inhibitors / therapeutic use*
  • Heterocyclic Compounds, 3-Ring / metabolism
  • Heterocyclic Compounds, 3-Ring / therapeutic use*
  • Humans
  • Lipid Metabolism / drug effects*
  • Lipoproteins / metabolism
  • Lipoproteins, LDL / metabolism
  • Longitudinal Studies
  • Oxazines / metabolism
  • Oxazines / therapeutic use*
  • Piperazines / metabolism
  • Piperazines / therapeutic use*
  • Pyridones / metabolism
  • Pyridones / therapeutic use*
  • Young Adult

Substances

  • Anti-Retroviral Agents
  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Lipoproteins
  • Lipoproteins, LDL
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir